Covid-19 Immunity Re-understood
Imagine discovering COVID-19 antibody tests have been looking for the wrong antibodies, until now…
Antibody tests aim to detect the parts of the immune response that only bind to the SARS-CoV-2 virus. However, until now, the majority of antibody tests may prove to have been looking for the wrong type of antibodies, neither unique to COVID-19 infection, nor as long lived.
Introducing our professional laboratory service, exclusively using the COVID-19 BioCard ™platform.
The BioCard™ is unique. No other rapid technology detects the same spike specific antibodies to past COVID-19 infection or detects these antibodies in as low concentrations.
By omitting commonly used generic materials, the BioCard™ avoids giving a positive result to antibodies produced following a common cold.
Spike antibodies from vaccination alone commonly wane within 6 months, or less.
Following natural (including asymptomatic) exposure the specific antibodies detected by the BioCard™ have been shown to persist for up to 20 months without any vaccine being administered… and counting. Rewriting our understanding of immunity to the SARS-COV-2 virus, with obvious and far reaching consequences for the world…
Entirely UK Researched, Made and Tested.
Outperforming many laboratory analysers, the BioCard ™has demonstrated its ability to detect antibodies from the MHRA NIBSC positive in low level, and is CE Marked and regulated under the Medicines and Healthcare Products Regulatory Agency. (MHRA).
Bio Diagnostics participate in the UK NEQAS SARS CoV-2 Antibody scheme to monitor the performance of the BioCard™.
BioCard™ is the only spike specific ultra-rapid IVD in the most recent UK NEQAS distribution, which detected the MHRA NIBSC positive control at 1:50.
Immunity Re-understood
Imagine discovering COVID-19 antibody tests have been looking for the wrong antibodies, until now…
Antibody tests aim to detect the parts of the immune response that only bind to the SARS-CoV-2 virus. However, until now, the majority of antibody tests may prove to have been looking for the wrong type of antibodies, neither unique to COVID-19 infection, nor as long lived.
Introducing our professional laboratory service, exclusively using the COVID-19 BioCard ™platform.
The BioCard™ is unique. No other rapid technology detects the same spike specific antibodies to past COVID-19 infection or detects these antibodies in as low concentrations.
By omitting commonly used generic materials, the BioCard™ avoids giving a positive result to antibodies produced following a common cold.
The specific antibodies detected by the BioCard™ have been shown to persist for 8 months, and counting, rewriting our understanding of immunity to the SARS-COV-2 virus, with obvious and far reaching consequences for the world…
Entirely UK Researched, Made and Tested.
Outperforming many laboratory analysers, the BioCard ™has demonstrated its ability to detect antibodies from the MHRA NIBSC positive in low level, and is CE Marked and regulated under the Medicines and Healthcare Products Regulatory Agency. (MHRA).
Bio Diagnostics participate in the UK NEQAS SARS CoV-2 Antibody scheme to monitor the performance of the BioCard™.
BioCard™ is the only spike specific ultra-rapid IVD in the most recent UK NEQAS distribution, which detected the MHRA NIBSC positive control at 1:50.